Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.

@article{Stanford2003AssociationOH,
  title={Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.},
  author={Janet L. Stanford and Leah P. Sabacan and Elizabeth A. Noonan and Lori Iwasaki and Jianfen Shu and Ziding Feng and Elaine A Ostrander},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={2003},
  volume={12 9},
  pages={876-81}
}
Genetic polymorphism in HPC2/ELAC2 was recently associated with risk of sporadic prostate cancer. To determine the contribution of two HPC2/ELAC2 missense variants (Ser217Leu and Ala541Thr) to the risk of developing prostate cancer, we conducted a population-based case-control study of middle-aged men (40-64 years). Cases (n=591) were ascertained from the… CONTINUE READING